- Home
- ATRC vs ANIP Comparison
ATRC vs ANIP Comparison
Compare ATRC & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRC
- ANIP
- Stock Information
- Founded
- ATRC 2000
- ANIP 2001
- Country
- ATRC United States
- ANIP United States
- Employees
- ATRC N/A
- ANIP N/A
- Industry
- ATRC Medical/Dental Instruments
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- ATRC Health Care
- ANIP Health Care
- Exchange
- ATRC Nasdaq
- ANIP Nasdaq
- Market Cap
- ATRC 1.1B
- ANIP 1.2B
- IPO Year
- ATRC 2005
- ANIP N/A
- Fundamental
- Price
- ATRC $38.39
- ANIP $57.94
- Analyst Decision
- ATRC Strong Buy
- ANIP Buy
- Analyst Count
- ATRC 10
- ANIP 7
- Target Price
- ATRC $49.50
- ANIP $77.33
- AVG Volume (30 Days)
- ATRC 539.4K
- ANIP 165.0K
- Earning Date
- ATRC 02-12-2025
- ANIP 02-28-2025
- Dividend Yield
- ATRC N/A
- ANIP N/A
- EPS Growth
- ATRC N/A
- ANIP N/A
- EPS
- ATRC N/A
- ANIP N/A
- Revenue
- ATRC $465,307,000.00
- ANIP $555,456,000.00
- Revenue This Year
- ATRC $14.41
- ANIP $25.54
- Revenue Next Year
- ATRC $12.87
- ANIP $20.95
- P/E Ratio
- ATRC N/A
- ANIP N/A
- Revenue Growth
- ATRC 16.55
- ANIP 23.60
- 52 Week Low
- ATRC $18.94
- ANIP $52.50
- 52 Week High
- ATRC $43.11
- ANIP $70.81
- Technical
- Relative Strength Index (RSI)
- ATRC 47.41
- ANIP 46.25
- Support Level
- ATRC $37.72
- ANIP $58.37
- Resistance Level
- ATRC $42.68
- ANIP $60.54
- Average True Range (ATR)
- ATRC 1.78
- ANIP 1.69
- MACD
- ATRC -0.59
- ANIP -0.21
- Stochastic Oscillator
- ATRC 13.51
- ANIP 20.28
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.